NASDAQ · BDTX
Healthcare · Biotechnology
$2.21
Up+$0.06 (+2.79%)
Updated Aug 22, 2026, 11:57 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
BDTX closed at $2.21 after 21 trading sessions, up 25.57% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $2.15 | $2.26 | $2.15 | $2.21 | 656.73K |
| Aug 20, 2026 | $2.17 | $2.19 | $2.08 | $2.15 | 1.14M |
| Aug 19, 2026 | $2.08 | $2.21 | $2.08 | $2.19 | 827.22K |
| Aug 18, 2026 | $2.05 | $2.08 | $2.02 | $2.06 | 474.81K |
| Aug 17, 2026 | $2.01 | $2.085 | $2.01 | $2.05 | 389.8K |
| Aug 14, 2026 | $2.01 | $2.045 | $1.9601 | $2.02 | 330.41K |
| Aug 13, 2026 | $2.12 | $2.12 | $2.00 | $2.02 | 489.1K |
| Aug 12, 2026 | $2.12 | $2.14 | $2.02 | $2.10 | 645.62K |
| Aug 11, 2026 | $2.01 | $2.10 | $1.95 | $2.09 | 812.74K |
| Aug 10, 2026 | $1.95 | $2.02 | $1.9302 | $1.98 | 665K |
| Aug 7, 2026 | $1.94 | $1.985 | $1.905 | $1.95 | 599.94K |
| Aug 6, 2026 | $1.80 | $1.935 | $1.76 | $1.92 | 748.14K |
| Aug 5, 2026 | $1.77 | $1.825 | $1.76 | $1.79 | 384.23K |
| Aug 4, 2026 | $1.80 | $1.82 | $1.735 | $1.78 | 917.2K |
| Aug 3, 2026 | $1.73 | $1.75 | $1.675 | $1.735 | 429.64K |
| Jul 31, 2026 | $1.71 | $1.71 | $1.62 | $1.69 | 623.02K |
| Jul 30, 2026 | $1.68 | $1.72 | $1.65 | $1.715 | 536.44K |
| Jul 29, 2026 | $1.76 | $1.775 | $1.64 | $1.66 | 870.14K |
| Jul 28, 2026 | $1.76 | $1.77 | $1.685 | $1.76 | 1.06M |
| Jul 27, 2026 | $1.77 | $1.845 | $1.725 | $1.73 | 625.21K |
| Jul 24, 2026 | $1.83 | $1.83 | $1.75 | $1.76 | 623.29K |
The latest Smart Investors Daily articles mentioning BDTX.
BDTX research
Company profile and research snapshot.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 29, 2026 | BTIG | Buy | — |
| Mar 17, 2026 | Wedbush | Outperform | — |
| Jan 16, 2026 | Piper Sandler | Overweight | — |
| Dec 4, 2025 | Guggenheim | Neutral | — |
| Oct 16, 2025 | Stifel | Buy | — |
No generated briefing is available yet.
Benzinga · May 7, 2026
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.03) by 433.33 percent. This is a 116.33 percent decrease over earnings of $0.98
Finnhub · May 7, 2026
CAMBRIDGE, Mass. — CAMBRIDGE, Mass. — Black Diamond Therapeutics, Inc. on Thursday reported a first-quarter loss of $9 million, after reporting a profit in the same period a year earlier. The...
Finnhub · May 7, 2026
Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual MeetingFirst patient dosed in the Phase...
Benzinga · Apr 29, 2026
BTIG analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises the price target from $10 to $11.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BDTX.
